Other mechanisms for the combinatorial effects of CDK4/6 and MEK inhibition in the KRAS-driven lung adenocarcinoma model may also be contributing, including an induction of senescence not observed after exposure to palbociclib alone. Here, CDK4 is linked to lung adenocarcinoma.